How Can You Avoid the Fallout From Incompatibility Between Your API and Its Formulation?
Small Molecule API
Author: Matthew Jones, Sr. Scientist, Head of Crystallization Lab, Patheon
Wednesday, September 06, 2017
In drug development, designing a formulation for a drug product (a tablet, for example) calls for careful attention to both the physical and chemical properties of the active pharmaceutical ingredient (API or drug substance). It also requires awareness that certain physical attributes, such as particle size distribution of the drug substance, can change with processing conditions and changes in the synthesis route that is employed.
Find out how a pharmaceutical company can recognize both unfavorable drug substance properties and incompatibility between an API and its formulation to avoid potential risks to the patient as well as costly interruptions during development.
Please complete the short form below to download this whitepaper